A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation - PubMed (original) (raw)
Clinical Trial
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al. Cancer Chemother Pharmacol. 2010 Jan.
Abstract
Purpose: We undertook a phase I/II study of the EGFR/erbB2 inhibitor lapatinib in patients with recurrent glioblastoma multiforme (GBM) to determine response rate, pharmacokinetics (PK) and recommended dose in patients taking enzyme-inducing anti-epileptic drugs (EIAEDs) and to explore relationships of molecular genetics to outcome.
Methods: Recurrent GBM patients taking EIAEDs were enrolled on the phase I portion (starting dose of lapatinib 1,000 mg po bid). In the absence of dose-limiting toxicity (DLT), escalation continued in cohorts of three patients. Patients not on EIAEDs enrolled in the phase II arm (lapatinib 750 mg bid po). Immunohistochemical and quantitative RT PCR studies were performed on tumor to determine PTEN and EGFRvIII status, respectively. Lapatinib PK was analyzed using HPLC with tandem mass spectrometry.
Results: Phase II: Of 17 patients, 4 had stable disease and 13 progressed. Accrual ceased because of no responses. Phase I: Four patients received 1,000 mg bid and three, 1,500 mg bid. No DLT occurred, but escalation stopped because of lack of phase II efficacy. Lapatinib apparent oral clearance in patients taking EIAEDs was 106.9 L h(-1) m(-2) in comparison to 12.1 L h(-1) m(-2) in those not on EIAEDs. In 16 phase II patients, PTEN loss was seen in 6 and EGFRvIII expression in 4. No correlation was seen with outcome and molecular results.
Conclusions: Lapatinib apparent oral clearance increased by approximately tenfold when given with EIAEDs. In this small sample, EGFRvIII expression and PTEN loss did not predict a favorable subtype. Overall, lapatinib did not show significant activity in GBM patients.
Similar articles
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Cloughesy TF, et al. J Clin Oncol. 2006 Aug 1;24(22):3651-6. doi: 10.1200/JCO.2006.06.2323. J Clin Oncol. 2006. PMID: 16877733 Clinical Trial. - A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. Reardon DA, et al. Clin Cancer Res. 2013 Feb 15;19(4):900-8. doi: 10.1158/1078-0432.CCR-12-1707. Epub 2013 Jan 30. Clin Cancer Res. 2013. PMID: 23363814 Clinical Trial. - Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T. van den Bent MJ, et al. J Clin Oncol. 2009 Mar 10;27(8):1268-74. doi: 10.1200/JCO.2008.17.5984. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204207 Free PMC article. Clinical Trial. - Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ, Goodin S. Medina PJ, et al. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
Cited by
- A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies.
Irwin ME, Johnson BP, Manshouri R, Amin HM, Chandra J. Irwin ME, et al. Oncotarget. 2015 Sep 15;6(27):23631-46. doi: 10.18632/oncotarget.4604. Oncotarget. 2015. PMID: 26136341 Free PMC article. - Liposomal Lapatinib in Combination with Low-Dose Photodynamic Therapy for the Treatment of Glioma.
Fisher C, Obaid G, Niu C, Foltz W, Goldstein A, Hasan T, Lilge L. Fisher C, et al. J Clin Med. 2019 Dec 14;8(12):2214. doi: 10.3390/jcm8122214. J Clin Med. 2019. PMID: 31847378 Free PMC article. - Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?
Montella L, Del Gaudio N, Bove G, Cuomo M, Buonaiuto M, Costabile D, Visconti R, Facchini G, Altucci L, Chiariotti L, Della Monica R. Montella L, et al. Front Oncol. 2022 Jul 6;12:926967. doi: 10.3389/fonc.2022.926967. eCollection 2022. Front Oncol. 2022. PMID: 35875139 Free PMC article. Review. - Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells.
Buendia Duque M, Pinheiro KV, Thomaz A, da Silva CA, Freire NH, Brunetto AT, Schwartsmann G, Jaeger M, de Farias CB, Roesler R. Buendia Duque M, et al. J Mol Neurosci. 2019 May;68(1):49-57. doi: 10.1007/s12031-019-01280-5. Epub 2019 Mar 18. J Mol Neurosci. 2019. PMID: 30887411 - Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.
Huang W, Hao Z, Mao F, Guo D. Huang W, et al. Front Oncol. 2022 Jun 17;12:911876. doi: 10.3389/fonc.2022.911876. eCollection 2022. Front Oncol. 2022. PMID: 35785151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous